Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non–Small-Cell Lung Cancer

Abstract

Although the study was terminated early, preoperative gemcitabine plus cisplatin followed by radical surgery improved survival in patients with clinical stage IIB/IIIA NSCLC.

Minimally invasive (robotic assisted thoracic surgery and video-assisted thoracic surgery) lobectomy for the treatment of locally advanced non-small cell lung cancer

“…In patients undergoing complete surgical resection adjuvant chemotherapy has been shown to benefit patients with pathological stage II-III disease (24,25). However, the ability for patients having a traditional thoracotomy to receive adjuvant chemotherapy has been limited.…”

Survival Analysis in Advanced Non Small Cell Lung Cancer Treated with Platinum Based Chemotherapy in Combination with Paclitaxel, Gemcitabine and Etoposide

“…But median survival varied within these groups of patients who received carboplatin and paclitaxel, the median survival was 10.18 months, 7.5 months in gemcitabine+carboplatin and 7 months in Cisplatin+etoposide regimen ( Table 2). The results of our study were in comparison with those reported by Scagliotti (2012) in their "clinical trialChEST", with a significant improvement in both disease free survival (DFS) (HR=0.51) and overall survival rate (HR=0.42) in patients with clinical stage IIB-IIIA NSCLC using preoperative gemcitabine plus cisplatin. However there was better improvement in Carboplatin+Paclitaxel regimen in the overall survival rate among the three treatment groups.…”

Perioperative chemotherapy for non-small-cell lung carcinoma: problems and solutions

“…Пациенты со ста-дией заболевания N2 в набор не включались [12]. Исследователи планировали включить 712 пациен-тов, но исследование было закрыто преждевремен-но, когда было набрано всего 270 пациентов, после www.…”

“…Общая выживаемость также была выше в группе химиотерапии. Исследователи задо-кументировали абсолютное трехлетнее улучшение в БРВ на 5.1% в группе «химиотерапия плюс опера-ция» и улучшение на 7.8% в 3-летней ОВ [12].…”